Please use this identifier to cite or link to this item: https://www.um.edu.mt/library/oar/handle/123456789/73231
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDi Fiore, Riccardo-
dc.contributor.authorSuleiman, Sherif-
dc.contributor.authorPentimalli, Francesca-
dc.contributor.authorO’Toole, Sharon A.-
dc.contributor.authorO’Leary, John J.-
dc.contributor.authorWard, Mark P.-
dc.contributor.authorConlon, Neil T.-
dc.contributor.authorSabol, Maja-
dc.contributor.authorOzretić, Petar-
dc.contributor.authorErson-Bensan, Ayse Elif-
dc.contributor.authorReed, Nicholas-
dc.contributor.authorGiordano, Antonio-
dc.contributor.authorHerrington, Simon-
dc.contributor.authorCalleja-Agius, Jean-
dc.date.accessioned2021-04-08T07:36:00Z-
dc.date.available2021-04-08T07:36:00Z-
dc.date.issued2021-
dc.identifier.citationDi Fiore, R., Suleiman, S., Pentimalli, F., O’Toole, S. A., O’Leary, J. J., Ward M. P.,…Calleja-Agius, J. (2021). Could MicroRNAs be useful tools to improve the diagnosis and treatment of rare gynecological cancers? A brief overview. International Journal of Molecular Sciences, 22, 3822.en_GB
dc.identifier.urihttps://www.um.edu.mt/library/oar/handle/123456789/73231-
dc.description.abstractGynecological cancers pose an important public health issue, with a high incidence among women of all ages. Gynecological cancers such as malignant germ-cell tumors, sex-cord-stromal tumors, uterine sarcomas and carcinosarcomas, gestational trophoblastic neoplasia, vulvar carcinoma and melanoma of the female genital tract, are defined as rare with an annual incidence of <6 per 100,000 women. Rare gynecological cancers (RGCs) are associated with poor prognosis, and given the low incidence of each entity, there is the risk of delayed diagnosis due to clinical inexperience and limited therapeutic options. There has been a growing interest in the field of microRNAs (miRNAs), a class of small non-coding RNAs of 22 nucleotides in length, because of their potential to regulate diverse biological processes. miRNAs usually induce mRNA degradation and translational repression by interacting with the 30 untranslated region (30-UTR) of target mRNAs, as well as other regions and gene promoters, as well as activating translation or regulating transcription under certain conditions. Recent research has revealed the enormous promise of miRNAs for improving the diagnosis, therapy and prognosis of all major gynecological cancers. However, to date, only a few studies have been performed on RGCs. In this review, we summarize the data currently available regarding RGCs.en_GB
dc.language.isoenen_GB
dc.publisherMDPIen_GB
dc.rightsinfo:eu-repo/semantics/openAccessen_GB
dc.subjectMicroRNAen_GB
dc.subjectGynecology -- Diagnosisen_GB
dc.subjectCancer -- Treatmenten_GB
dc.subjectVagina -- Canceren_GB
dc.subjectGenerative organs -- Canceren_GB
dc.titleCould MicroRNAs be useful tools to improve the diagnosis and treatment of rare gynecological cancers? A brief overviewen_GB
dc.typearticleen_GB
dc.rights.holderThe copyright of this work belongs to the author(s)/publisher. The rights of this work are as defined by the appropriate Copyright Legislation or as modified by any successive legislation. Users may access this work and can make use of the information contained in accordance with the Copyright Legislation provided that the author must be properly acknowledged. Further distribution or reproduction in any format is prohibited without the prior permission of the copyright holder.en_GB
dc.description.reviewedpeer-revieweden_GB
dc.identifier.doi10.3390/ijms22083822-
dc.publication.titleInternational Journal of Molecular Sciencesen_GB
Appears in Collections:Scholarly Works - FacM&SAna



Items in OAR@UM are protected by copyright, with all rights reserved, unless otherwise indicated.